Clinical trial
Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma
NCT00139360 · Haukeland University Hospital, Other · Completed
Key facts
| NCT number | NCT00139360 |
|---|---|
| Title | Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma |
| Official title | Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma and Predictive Value of Angiogenic Markers |
| Lead sponsor | Haukeland University Hospital, Other |
| Collaborators | Norwegian Cancer Society Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | Bevacizumab |
| Enrollment | 35 |
| Start date | May 1, 2005 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Aug 31, 2005 |
| Last update posted | Aug 27, 2015 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: